Literature DB >> 23725644

Sensitivity of cognitive tests in four cognitive domains in discriminating MDD patients from healthy controls: a meta-analysis.

JaeHyoung Lim1, In Kyung Oh, Changsu Han, Yu Jeong Huh, In-Kwa Jung, Ashwin A Patkar, David C Steffens, Bo-Hyoung Jang.   

Abstract

BACKGROUND: We performed a meta-analysis in order to determine which neuropsychological domains and tasks would be most sensitive for discriminating between patients with major depressive disorder (MDD) and healthy controls.
METHODS: Relevant articles were identified through a literature search of the PubMed and Cochrane Library databases for the period between January 1997 and May 2011. A meta-analysis was conducted using the standardized means of individual cognitive tests in each domain. The heterogeneity was assessed, and subgroup analyses according to age and medication status were performed to explore the sources of heterogeneity.
RESULTS: A total of 22 trials involving 955 MDD patients and 7,664 healthy participants were selected for our meta-analysis. MDD patients showed significantly impaired results compared with healthy participants on the Digit Span and Continuous Performance Test in the attention domain; the Trail Making Test A (TMT-A) and the Digit Symbol Test in the processing speed domain; the Stroop Test, the Wisconsin Card Sorting Test, and Verbal Fluency in the executive function domain; and immediate verbal memory in the memory domain. The Finger Tapping Task, TMT-B, delayed verbal memory, and immediate and delayed visual memory failed to separate MDD patients from healthy controls. The results of subgroup analysis showed that performance of Verbal Fluency was significantly impaired in younger depressed patients (<60 years), and immediate visual memory was significantly reduced in depressed patients using antidepressants.
CONCLUSIONS: Our findings have inevitable limitations arising from methodological issues inherent in the meta-analysis and we could not explain high heterogeneity between studies. Despite such limitations, current study has the strength of being the first meta-analysis which tried to specify cognitive function of depressed patients compared with healthy participants. And our findings may provide clinicians with further evidences that some cognitive tests in specific cognitive domains have sensitivity to discriminate MDD patients from healthy controls.

Entities:  

Mesh:

Year:  2013        PMID: 23725644     DOI: 10.1017/S1041610213000689

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  21 in total

Review 1.  Diagnosis and treatment of depression and cognitive impairment in late life.

Authors:  Sarah Shizuko Morimoto; Dora Kanellopoulos; Kevin J Manning; George S Alexopoulos
Journal:  Ann N Y Acad Sci       Date:  2015-02-05       Impact factor: 5.691

2.  Development and evaluation of a multimodal marker of major depressive disorder.

Authors:  Jie Yang; Mengru Zhang; Hongshik Ahn; Qing Zhang; Tony B Jin; Ien Li; Matthew Nemesure; Nandita Joshi; Haoran Jiang; Jeffrey M Miller; Robert Todd Ogden; Eva Petkova; Matthew S Milak; Mary Elizabeth Sublette; Gregory M Sullivan; Madhukar H Trivedi; Myrna Weissman; Patrick J McGrath; Maurizio Fava; Benji T Kurian; Diego A Pizzagalli; Crystal M Cooper; Melvin McInnis; Maria A Oquendo; Joseph John Mann; Ramin V Parsey; Christine DeLorenzo
Journal:  Hum Brain Mapp       Date:  2018-08-16       Impact factor: 5.038

3.  State of the Science of Neural Systems in Late-Life Depression: Impact on Clinical Presentation and Treatment Outcome.

Authors:  Kevin J Manning; David C Steffens
Journal:  J Am Geriatr Soc       Date:  2018-04       Impact factor: 5.562

4.  The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers.

Authors:  Akemi Miyata; Kunihiro Iwamoto; Naoko Kawano; Kunihiro Kohmura; Maeri Yamamoto; Branko Aleksic; Kazutoshi Ebe; Akiko Noda; Yukihiro Noda; Shuji Iritani; Norio Ozaki
Journal:  Psychopharmacology (Berl)       Date:  2014-12-24       Impact factor: 4.530

5.  Single-session transcranial direct current stimulation induces enduring enhancement of visual processing speed in patients with major depression.

Authors:  Nadine Gögler; Lina Willacker; Johanna Funk; Wolfgang Strube; Simon Langgartner; Natan Napiórkowski; Alkomiet Hasan; Kathrin Finke
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-12-30       Impact factor: 5.270

6.  The Age Limit Does Not Exist: A Pilot Usability Assessment of a SMS-Messaging and Smartwatch-Based Intervention for Older Adults with Depression.

Authors:  Natalie C Benda; George S Alexopoulos; Patricia Marino; Jo Anne Sirey; Dimitris Kiosses; Jessica S Ancker
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25

7.  The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial.

Authors:  Regina L Leckie; David E Lehman; Peter J Gianaros; Kirk I Erickson; Susan M Sereika; Dora C H Kuan; Stephen B Manuck; Christopher M Ryan; Jeffrey K Yao; Matthew F Muldoon
Journal:  Psychol Med       Date:  2019-10-04       Impact factor: 7.723

Review 8.  Measuring cognitive function in MDD: emerging assessment tools.

Authors:  Manuela Russo; Katie Mahon; Katherine E Burdick
Journal:  Depress Anxiety       Date:  2014-11-24       Impact factor: 6.505

Review 9.  Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease.

Authors:  Flavie Darcet; Alain M Gardier; Raphael Gaillard; Denis J David; Jean-Philippe Guilloux
Journal:  Pharmaceuticals (Basel)       Date:  2016-02-17

10.  Intrinsic connectivity of the prefrontal cortex and striato-limbic system respectively differentiate major depressive from generalized anxiety disorder.

Authors:  Xiaolei Xu; Jing Dai; Yuanshu Chen; Congcong Liu; Fei Xin; Xinqi Zhou; Feng Zhou; Emmanuel A Stamatakis; Shuxia Yao; Lizhu Luo; Yulan Huang; Jinyu Wang; Zhili Zou; Deniz Vatansever; Keith M Kendrick; Bo Zhou; Benjamin Becker
Journal:  Neuropsychopharmacology       Date:  2020-09-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.